The metabolic governor. Rarely examined correctly.
TSH alone is a pituitary signal, not a tissue signal. Free T3 is the active hormone. Reverse T3 is the brake. A patient with a normal TSH can have subclinical hypothyroidism that blunts every anabolic protocol. Most clinicians never order the full panel.
I. Thyroid hormone hierarchy.
The hypothalamic-pituitary-thyroid (HPT) axis governs thyroid output through a cascade: the hypothalamus releases TRH (thyrotropin-releasing hormone), which stimulates the anterior pituitary to release TSH (thyroid-stimulating hormone), which in turn drives thyroid production of T4 (thyroxine, the storage form) and T3 (triiodothyronine, the active form). verified
T4 is converted peripherally, primarily in the liver and skeletal muscle, to T3 via deiodinase enzymes (DIO1, DIO2). This peripheral conversion is the critical step. The thyroid does not deliver finished, active hormone to tissue. It delivers precursor. The conversion step is where the clinical picture is most often missed. verified [I]
Reverse T3 (rT3) is an inactive isomer produced from T4 under conditions of physiological stress, caloric restriction, inflammation, selenium deficiency, and elevated cortisol. Reverse T3 competes with T3 at tissue receptors, functionally reducing thyroid activity even when circulating T4 levels appear normal. The patient has the precursor. The conversion went the wrong direction. verified [I]
II. The TSH-only screening failure.
TSH reflects pituitary feedback, not tissue-level T3 activity. A patient can present with a normal TSH, low-normal free T3, and elevated rT3, producing a clinically hypothyroid phenotype with a completely normal lab result on standard panels. The pituitary is satisfied. The tissues are not. verified
The Standard of Care Failure
The standard of care in most primary care settings is TSH only. This is insufficient for any patient on an optimization protocol. TSH does not measure what the tissues are receiving. Free T3 and reverse T3 are required to assess the complete picture. Clinicians who order TSH only and declare "thyroid is fine" have not evaluated thyroid function. They have evaluated pituitary feedback. These are not the same measurement. They never were.
The Pivotal standard thyroid panel: TSH + free T4 + free T3 + reverse T3. Four labs. Not one.
Optimal ranges for optimization (not laboratory reference ranges): TSH 0.5 to 2.0 mIU/L; free T4 1.1 to 1.5 ng/dL; free T3 3.2 to 4.2 pg/mL; reverse T3 below 15 ng/dL; free T3-to-reverse T3 ratio above 20. Laboratory reference ranges are calibrated to population averages, including the subclinically hypothyroid majority. They are not calibrated to optimal metabolic function. optimization targets, clinical practice
III. Subclinical hypothyroidism and the optimization patient.
Subclinical hypothyroidism (SCH) is defined as TSH elevated above 4.5 mIU/L with normal free T4. Prevalence is approximately 4 to 8% of adults, making it one of the more common endocrine findings in an optimization population. verified [II]
The clinical consequence of SCH is not trivial. Biondi and Cooper (2008) document association with dyslipidemia, elevated cardiovascular risk, cognitive symptoms, and blunted response to exercise. The patient with unaddressed SCH who begins a testosterone or GH secretagogue protocol will underperform relative to expectation. The protocol is running, but the metabolic machinery to respond to it is throttled. verified [II]
Optimal thyroid function is associated with increased basal metabolic rate, improved insulin sensitivity, better lipid profile, and enhanced protein synthesis rate. These are not peripheral benefits. They are the substrate conditions that determine whether an optimization protocol performs as designed or underdelivers. verified [V]
IV. Reverse T3 elevation and the high-cortisol patient.
Chronic stress, caloric restriction (particularly low-carbohydrate diets below 50g per day), overtraining, and elevated cortisol all shift T4 conversion toward rT3 rather than active T3. The patient who is already under physiological load is the patient most likely to have impaired thyroid activation, and least likely to have it detected on a standard panel. verified [V]
Patients on aggressive caloric deficit, including GLP-1 protocols without adequate carbohydrate cycling, carry elevated risk for rT3 accumulation. The weight loss is visible. The thyroid impairment is not.
rT3 clearance strategy: the primary intervention is removing the stressor driving the conversion. Reduce cortisol load, cycle calories upward, reduce overtraining volume. Selenium adequacy supports the DIO enzymes responsible for T4-to-T3 conversion. Supplemental selenomethionine at 200 mcg per day addresses selenium deficiency in patients who test low or who present with the clinical picture. Brazil nuts are a dietary source but inconsistent in dose. verified
V. When to consider thyroid support.
Free T3 below 3.0 pg/mL in the presence of symptoms, including fatigue, cold intolerance, cognitive slowing, constipation, hair thinning, or weight resistance, warrants endocrinology referral and formal evaluation. These are not vague complaints. They are the expected clinical expression of insufficient tissue T3 activity. verified [III]
T3 monotherapy and combination T4/T3 (desiccated thyroid extract) are outside the scope of this note. Both require endocrinology or functional medicine specialist involvement. The operator role at this tier is identification and referral, not prescription.
Iodine adequacy: thyroid hormone synthesis requires dietary iodine. Iodine deficiency is more prevalent than most clinicians expect, particularly in patients who avoid iodized salt. Urinary iodine assessment is available and rarely ordered. It belongs on the intake workup in symptomatic patients. clinical practice recommendation
Selenium: an essential cofactor for DIO enzymes. Selenomethionine at 200 mcg per day in deficient patients supports T4-to-T3 conversion. Selenium status is rarely assessed in routine panels and is worth including in the full metabolic workup. verified [I]
VI. Clinical workflow.
Order the full panel at intake: TSH, free T4, free T3, reverse T3. Not TSH alone. The four-panel draw costs approximately the same as a comprehensive metabolic panel. The information gap between TSH-only and the full panel is not small. verified [IV]
Calculate the free T3-to-reverse T3 ratio. Flag any ratio below 20. Flag free T3 below 3.2 pg/mL. Flag reverse T3 above 15 ng/dL.
If free T3 is low-normal or rT3 is elevated, investigate the cortisol pattern (4-point salivary cortisol or serum AM/PM cortisol), dietary carbohydrate intake, training volume, and caloric deficit depth. These are the four most common drivers. Address them in order of clinical weight.
Recheck at 90 days after any intervention. Thyroid panels taken in the context of acute stressors reflect the stressor as much as the underlying thyroid status. A second draw after lifestyle correction is required before drawing conclusions.
Protocol gate: do not launch a GH secretagogue or testosterone protocol in a patient with a flagged thyroid panel without addressing the thyroid tier first. At minimum, document the finding and record the clinical decision to proceed. A patient who underperforms on a protocol with an unaddressed thyroid finding is not a protocol failure. It is a screening failure.
References
- Bianco AC et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38-89. Foundational selenodeiodinase biochemistry, rT3 production mechanism, selenium cofactor role. verified
- Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76-131. Subclinical hypothyroidism prevalence, cardiovascular associations, lipid effects, cognitive and exercise response. verified
- Jonklaas J et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. Treatment thresholds, T3 monotherapy evidence, symptom criteria for evaluation. verified
- Idrees T, Palmer S. How to interpret thyroid tests. Cleve Clin J Med. 2023;90(1):47-54. Practical panel interpretation, optimization range context, free T3 and rT3 clinical use. verified
- Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382. Basal metabolic rate, insulin sensitivity, lipid metabolism, protein synthesis. verified
THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The mechanisms described here are derived from the cited literature and from Pivotal's own protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.